Hire UI/UX Designer for Biotech Startups
Senior, direct, no layers

The scarcest resource at a biotech startup is focused scientific time. Every hour a scientist spends reformatting data, chasing a CRO, or rebuilding an investor update is an hour not spent on the science the company exists to do. The recurring friction is experimental data scattered across notebooks and drives, CRO results arriving late or in unusable formats, and investor updates rebuilt from scratch every month.

A UI/UX designer shapes the screens people actually use: the booking flow, the record view, the checkout, the dashboard. For biotech startups, that means design grounded in assay development and validation as staff and research partners, investors, and CRO teams experience it, tested with real users before it is built.

Picture a CRO dataset arriving in a format nobody can use, days before an investor update is due. In that situation, a flow designed around the user's actual task — with the next step obvious and errors handled gracefully — would remove the hesitation that currently stalls the whole journey. Book a free discovery call and we will test the fit on one real workflow before any wider scope is agreed.

The stack here is an electronic lab notebook such as Benchling, a LIMS, bioinformatics pipelines, and CRO data portals. The gap is usually connection, not tools: work lands in one system, records live in another, and nobody has one view of where a case stands. This engagement connects that stack and standardises the routines around it.

The design work sits alongside an electronic lab notebook such as Benchling and a LIMS as they exist, respecting their constraints instead of designing screens the systems cannot support. Handover notes name where a design choice depends on a system behavior.

This page describes services, not scientific or regulatory advice. Research and regulatory decisions stay with the startup's qualified scientific staff. FDA IND and BLA pathways shapes what can be automated or changed, and the work is scoped to fit it rather than work around it.

The realistic outcome is data the team can actually use: experiments findable, CRO results comparable, and updates assembled from real results instead of rebuilt each time.

Two problems deserve naming: experimental data scattered across notebooks and drives and CRO results arriving late or in unusable formats. Both persist when the underlying routine stays manual and nobody owns the follow-up, so each deliverable in this engagement is paired with a named owner and a visible queue, and problems surface while they are still small.

What changes is completion: more users finish the task, fewer ask for help halfway through, and the team stops fielding the same usability complaints.

Browse all hire engagements or discuss your biotech startup workflow directly.